Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis | Zendy

Kimberly Robeson | Zendy; Aditya Kumar | Zendy; Benison Keung | Zendy; Daniel DiCapua | Zendy; Emily Grodinsky | Zendy; Huned Patwa | Zendy; Panos Stathopoulos | Zendy; Jonathan Goldstein | Zendy; Kevin C. O’Connor | Zendy; Richard J. Nowak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis

Author(s) -

Kimberly Robeson,

Aditya Kumar,

Benison Keung,

Daniel DiCapua,

Emily Grodinsky,

Huned Patwa,

Panos Stathopoulos,

Jonathan Goldstein,

Kevin C. O’Connor,

Richard J. Nowak

Publication year - 2016

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2016.4190

Subject(s) - rituximab , myasthenia gravis , medicine , refractory (planetary science) , autoantibody , gastroenterology , acetylcholine receptor , retrospective cohort study , immunology , antibody , receptor , lymphoma , physics , astrobiology

Myasthenia gravis (MG), an autoimmune disorder of neuromuscular transmission, is treated by an array of immunotherapeutics, many of which are nonspecific. Even with current therapies, a subset of patients has medically refractory MG. The benefits of B-cell-targeted therapy with rituximab have been observed in MG; however, the duration of these benefits after treatment is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research